You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

5 search results for: remission

expert video

What Could Remission Mean in AD?

1 min

Dermatology

Dr. Simpson explores the concept of remission in AD, focusing on minimal disease activity and long-term remission, discussing how disease modification in AD can impact the course of the disease and its associated comorbidities.

Current systemic therapies have been shown to induce <b>remission</b> in a subset of AD patients

expert video

Current systemic therapies have been shown to induce remission in a subset of AD patients

5 min

Dermatology

Dr. Ramien discusses evidence suggesting early targeted inhibition in pediatric patients may prevent disease progression or lead to remission.

Podcast

ADVENT On Air | Charting a New Course: The Frontier of Early Intervention and Disease Modification in AD

23 min

Dermatology

Join Drs. April Armstrong and Lisa Beck for a conversation around the long-term burden and effects of AD. They will discuss the underlying pathophysiology of AD and how early intervention and disease modification may impact disease course.

Podcast

ADVENT On Air | Expert Discussions in Dermatology

45 min

Dermatology

Listen to the latest updates in type 2 inflammatory science and associated skin diseases, brought to you by leading dermatology experts in the field. ADVENT On Air podcasts feature scientific conversations that explore new research into the pathophysiology, clinical features, and disease burden for a range of dermatological diseases linked to type 2 inflammation, including atopic dermatitis (AD) and prurigo nodularis (PN). Hear new insights revealed through expert-led conversations below or in your preferred podcast app.

Infographic

CCL17 (TARC): A Key Player and Biomarker in Atopic Dermatitis

5 min

Dermatology

An infographic to explore the the key roles of CCL17 (TARC) in atopic dermatitis.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: South AfricaChange country/region